Pall Biotech has announced a new end-to-end integrated platform solution that accelerates development, reduces risk and simplifies your process for gene therapy manufacturing.
The company provides a fully integrated, scalable, and single-use gene therapy solution from development through to commercialisation, from upstream and downstream processing through to formulation and filling.
Key features include:
- Simplify and streamline your process while reducing the risk for operator error
- Reduce time-to-market
- Reduce overall cost of goods
A presentation explaining this feature is available. Depending on your preference, Pall Biotech can arrange for an on-site visit by one of its technical specialists or a presentation can be delivered via webex.
Contact the company using the enquiry form for more information.